AbbVie Completes Acquisition of Capstan Therapeutics
1. AbbVie acquires Capstan Therapeutics, enhancing its immunology pipeline. 2. Capstan's lead candidate aims for drug-free remission in B cell diseases. 3. Acquisition strengthens AbbVie's capabilities in RNA delivery technology. 4. CPTX2309 shows promise without traditional lymphodepleting chemotherapy. 5. AbbVie plans to advance new treatments leveraging Capstan's expertise.